永田 哲也 (東京医科歯科大学病院 脳神経病態学(神経内科)分野)
At this symposium, world-leading scientists will talk about gene therapy / regenerative medicine with new modalities designed to overcome intractable neurological diseases.
Neuroscience Frontier Symposium
2019年5月25日(土) 08:00 〜 10:00 第3会場 (大阪国際会議場10F 会議室1003)
座長:岡澤 均(東京医科歯科大学難治疾患研究所神経病理学部門), 井上 治久(京都大学iPS細胞研究所増殖分化機構研究部門)
In 2017, an antisense oligonucleotide, nusinersen, was approved as the first treatment for spinal muscular atrophy (SMA). Nusinersen avoids the blood-brain barrier by being injected directly into the cerebrospinal spinal fluid space, and it also eclipsed the existing paradigm of neurological therapeutics. In addition, positive results of a clinical trial of SMA gene therapy using a neurotropic adeno-associated virus (AAV) type 9 were also announced. In 2018, furthermore, transplantation treatment using iPS cells / ES cells against Parkinson's disease was about to begin as an actual clinical trial.
At this symposium, world-leading scientists will talk about gene therapy / regenerative medicine with new modalities designed to overcome intractable neurological diseases.
永田 哲也 (東京医科歯科大学病院 脳神経病態学(神経内科)分野)
Martin Marsala1, Don W. Cleveland2, Brian K. Kaspar3, Mariana Bravo-hernandez1, Takahiro Tadokoro1 (1.University of California, San Diego, 2.Ludwig Institute for Cancer Research and Department of Cellular and Molecular Medicine, University of California at San Diego, La Jolla, USA;, 3.Avexis Inc., Chicago, USA)
村松 慎一1,2,3 (1.自治医科大学 神経内科学, 2.東京大学医科学研究所 遺伝子・細胞治療センター, 3.大阪大学 神経内科学)
岡澤 均1,2 (1.東京医科歯科大学 難治疾患研究所 神経病理学分野, 2.東京医科歯科大学 脳統合機能研究センター)
高橋 淳 (京都大学 iPS細胞研究所)